Crinetics Pharmaceuticals Inc

CRNX is in Stage 2 advancing with a strong parabolic momentum breakout but is extreme overbought and extended above the 9/21/50 EMAs; immediate entry is unfavorable. We recommend Stalk to wait for a shallow pullback into the 9/21/50 EMA zone or base breakout area before initiating long exposure.

• ↑Q1 revenue $10.7M (Palsonify $10.3M) shows early commercial traction
• ↑Cash position $1.3B supports R&D and ops into 2030
• ↓Profitability score indicates weak return generation and elevated leverage risk